

Vanthida Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1450645/publications.pdf>

Version: 2024-02-01

30
papers

689
citations

567281

15
h-index

552781

26
g-index

31
all docs

31
docs citations

31
times ranked

1036
citing authors

#	ARTICLE	IF	CITATIONS
1	Cleaning and disinfecting environmental surfaces in health care: Toward an integrated framework for infection and occupational illness prevention. <i>American Journal of Infection Control</i> , 2015, 43, 424-434.	2.3	125
2	Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	92
3	Risk of Serotonin Syndrome with Concomitant Administration of Linezolid and Serotonin Agonists. <i>Pharmacotherapy</i> , 2006, 26, 1784-1793.	2.6	67
4	Characterisation of a <i>Staphylococcus aureus</i> strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 564-568.	2.5	57
5	Ceftaroline fosamil monotherapy for methicillin-resistant <i>Staphylococcus aureus</i> bacteremia: a comparative clinical outcomes study. <i>International Journal of Infectious Diseases</i> , 2017, 57, 27-31.	3.3	40
6	Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant <i>Staphylococcus aureus</i> in an In Vitro Pharmacodynamic Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 302-308.	3.2	34
7	Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (<i>agr</i>) dysfunction among clinical bloodstream isolates of <i>staphylococcus aureus</i> . <i>BMC Infectious Diseases</i> , 2011, 11, 287.	2.9	29
8	Evaluation of daptomycin activity against <i>Staphylococcus aureus</i> in an in vitro pharmacodynamic model under normal and simulated impaired renal function. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 116-121.	3.0	25
9	The Emerging Role of β -Lactams in the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
10	Antibiotic Hypersensitivity Mechanisms. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 122.	1.6	22
11	Poly-L-lactic Acid for Facial Lipatrophy in HIV. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1602-1606.	1.9	20
12	Risk Factors for 30-Day Mortality in Patients with Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>International Journal of Infectious Diseases</i> , 2017, 61, 3-6.	3.3	19
13	Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 25-29.	2.5	18
14	The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1434-1438.	2.8	18
15	Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE). <i>Current Infectious Disease Reports</i> , 2016, 18, 48.	3.0	16
16	<i>Neisseria gonorrhoeae</i> and fosfomycin: Past, present and future. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 290-296.	2.5	12
17	Glycopeptide Hypersensitivity and Adverse Reactions. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 70.	1.6	12
18	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab606.	0.9	12

#	ARTICLE	IF	CITATIONS
19	In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci. Antimicrobial Agents and Chemotherapy, 2004, 48, 2719-2723.	3.2	11
20	Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage. International Journal of Antimicrobial Agents, 2020, 55, 105964.	2.5	9
21	Utilization of Augmented Renal Clearance in Trauma Intensive Care Scoring System to Improve Vancomycin Dosing in Trauma Patients at Risk for Augmented Renal Clearance. Surgical Infections, 2020, 21, 43-47.	1.4	8
22	Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections. Current Infectious Disease Reports, 2016, 18, 47.	3.0	7
23	Methicillin-Resistant Staphylococcus aureus in the Community. Infectious Diseases in Clinical Practice, 2005, 13, 93-95.	0.3	4
24	Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115442.	1.8	4
25	Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates. Microbiology Spectrum, 0, , .	3.0	2
26	Evaluation of in vitro susceptibility trends to vancomycin and daptomycin by strain type of Staphylococcus aureus causing bloodstream infections. Journal of Global Antimicrobial Resistance, 2014, 2, 280-285.	2.2	1
27	Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis. Surgical Infections, 2016, 17, 675-682.	1.4	1
28	Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	1
29	Evaluation of a Formulary Change on Outcome of Infection and Antimicrobial Resistance in a Medical Intensive Care Unit. Infectious Diseases in Clinical Practice, 2006, 14, 360-364.	0.3	0
30	Vancomycin Serum Trough Levels and Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia. Open Forum Infectious Diseases, 2016, 3, .	0.9	0